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ABSTRACT
Background: We showed previously that α-galactosylceramide (α-GalCer) treatment elevated splenic CD4+
CD25+Foxp3+ T-cell numbers and suppressed the development of experimental allergic conjunctivitis (EC).
Here, we investigated whether CD4+CD25+Foxp3+ T cells mediate the suppressive effects of α-GalCer treat-
ment on EC.
Methods: To deplete CD4+CD25+Foxp3+ T cells, neonatal mice were thymectomized and intraperitoneally in-
jected with anti-CD25 Ab. At 6 weeks of age, these mice were immunized with ragweed (RW) in aluminum hy-
droxide. Ten days later, the mice were challenged with RW in eye drops and 24 hours later, the conjunctivas
and spleens were harvested for histological and flow cytometric analyses, respectively. α-GalCer or vehicle
was injected 2 hours prior to RW challenge. In addition, α-GalCer was injected into thymus-intact EC-
developing mice that had not been treated with anti-CD25 Ab.
Results: α-GalCer treatment significantly suppressed EC in the thymus-intact mice that had not been treated
with anti-CD25 Ab. In contrast, α-GalCer treatment of thymectomized and anti-CD25 Ab-treated mice did not
affect the severity of EC or splenic CD4+CD25+Foxp3+ T-cell numbers. However, α-GalCer treatment did sig-
nificantly increase splenic CD4+CD25+Foxp3+ T-cell numbers in thymectomized mice that had not received
anti-CD25 Ab.
Conclusions: α-GalCer treatment during the effector phase of EC increased CD4+CD25+Foxp3+ T-cell num-
bers, which in turn suppressed the development of EC.
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INTRODUCTION
Allergic conjunctivitis (AC) is a disease that ranges
from mild forms such as seasonal AC to severe forms
such as vernal keratoconjunctivitis (VKC).1 More
than 80% of AC patients have mild forms of the dis-
ease and their major clinical findings are itching and
hyperemia.2 In contrast, the clinical manifestations of
VKC are proliferative conjunctival giant papillary for-
mations with intense itching, strong pain, foreign
body sensation, mucous discharge and corneal ul-
ceration, which may lead to vision loss. Cytological
and histological studies have shown that many
eosinophils infiltrate the conjunctiva of VKC pa-
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Fig. 1 Treatment with α-GalCer during the efector phase suppressed 
EC. BALB/c mice were immunized with RW in alum and 10 days later, the 
mice were chalenged with RW in eye drops. Two hours prior to RW chalen-
ge, α-GalCer (active＋α-GalCer) or vehicle (active ＋ vehicle) was injected 
intraperitonealy (n＝3 per group). Twenty-four hours after RW chalenge, 
the conjunctivas were harvested and the conjunctival eosinophils were 
counted. Alternatively, conjunctivas were harvested from unprimed mice 
that had been chalenged with RW and treated with either α-GalCer (un-
primed ＋α-GalCer) or vehicle (unprimed＋vehicle) (n＝3 per group). The 
data are presented as means＋/－ SEM of 3 mice in each group. ＊＊P＜
0.01.
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tients.3 Furthermore, the numbers of eosinophils in
tear fluids increase as the severity of corneal damage
increases.4 Thus, it is believed that eosinophils are
the major effector cells in the development of VKC.
However, AC is an Ag-specific disease and eosino-
phils do not have Ag-specific receptors. Therefore, T
cells or Igs, which have Ag-specific receptors, are be-
lieved to play a crucial role in the development of AC.
To examine this issue, our group has investigated the
mechanism by which VKC develops by using animal
models of AC (experimental AC, EC).5-10 Adoptive
transfer experiments demonstrated that Ag-primed T
cells, but not Ag-specific IgE, trigger conjunctival
eosinophil infiltration.11 Furthermore, adoptive trans-
fer of Ag-specific Th2 cells, but not Ag-specific Th1
cells or CD8+ T cells, was able to induce conjunctival
eosinophil infiltration.12 Thus, it appears that Th2
cells play an essential role in the development of EC
and possibly VKC as well.
Th2 cells are regulated in vivo by many types of
cells, including regulatory T cells (Tregs) and NKT
cells. The depletion of naturally occurring thymus-
selected Tregs augments the severity of EC,13,14
which demonstrates that Tregs regulate the develop-
ment of EC. We also found that the forced activation
of NKT cells by administration of α-galactosylcerami-
de (α-GalCer) during the effector phase of EC at-
tenuated the severity of EC.15 Interestingly, α-GalCer
treatment during the effector phase significantly in-
creased the numbers of splenic CD4+CD25+Foxp3+
Tregs.15 Therefore, we speculated that CD4+CD25+
Foxp3+ Tregs may mediate the attenuation of EC in-
duced by α-GalCer treatment during the effector
phase. Here, to test this notion, Treg-depleted mice
were treated with α-GalCer during the effector phase.
METHODS
MICE
Inbred BALBc mice were purchased from Japan
SLC Inc., Hamamatsu, Shizuoka, Japan, and kept in
pathogen-free conditions at the animal facility of the
Kochi Medical School. All research adhered to the
Association for Research in Vision and Ophthalmol-
ogy Statement for the Use of Animals in Ophthalmic
and Vision Research.
REAGENTS
Short ragweed pollen (RW) was purchased from
Polysciences, Inc, Warrington, PA, USA. RW extract
was obtained from LSL Co. Ltd., Tokyo, Japan. Alumi-
num hydroxide (alum) was purchased from Sigma,
St. Louis, MO, USA. α-GalCer was kindly donated by
Kirin, Tokyo, Japan.
THYMECTOMY, TREATMENT WITH ABS AND α-
GALCER AND INDUCTION OF EC
Neonates were thymectomized 3 days after birth as
described previously13 and then injected intraperito-
neally on days 4, 21 and 38 after birth with 150 μg of
rat mAbs against CD25 (PC61, rat IgG1, n = 17 ) or
α-GalCer-Induced CD4+CD25+ T Cells in AC
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Fig. 2 Flow cytometric analysis of CD25 and Foxp3 expression in 
CD4＋T-cel compartment. Thymectomized (Tx) mice were intraperito-
nealy injected with PC61 or nrIgG. These mice were immunized with 
RW and 10 days later, the mice were chalenged with RW in eye drops. 
Two hours before RW chalenge, the mice were injected intraperito-
nealy with either α-GalCer or vehicle. Twenty-four hours after RW chal-
lenge, spleens were harvested for flow cytometric analysis to determine 
the levels of Foxp3 expression. Expression levels of CD25 and Foxp3 
in CD4＋T-cel compartment are presented as dot plot. Representative 
data of each group summarized in Table 1 are shown.
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control rat IgG (MP Biomedicals Inc., Aurora, OH,
USA, n = 19). Six weeks after birth, RW (Poly-
sciences, Inc, Warrington, PA, USA) adsorbed on
alum (Sigma, St. Louis, MO, USA) was injected into
the left hind-footpad and the tail base; each site re-
ceived 50 μl emulsion, which contained 50 μg of RW
and 675 μg of alum. Ten days later, the eyes of the
immunized mice were challenged with RW in PBS (2
mg in 10 μl per eye). Two μg of α-GalCer was intrape-
ritoneally injected 2 hours before RW challenge (n =
9 in nrIgG-treated group and n = 8 in PC61-treated
group). As a control, the vehicle (polysorbate-20,
0.5%) was used. Twenty-four hours later, the eyes and
spleens were harvested for histological and flow cy-
tometric analyses, respectively. In addition, EC was
induced and α-GalCer or vehicle was injected in un-
thymectomized and unprimed naïve mice for histo-
logical analysis (n = 3 per group), as described above.
Furthermore, to evaluate the effect of thymectomy
alone on EC, EC was induced in thymectomized and
unthymectomized immunocompetent mice without
treatment of any Abs and α-GalCer or vehicle (n = 17
per group).
HISTOLOGICAL ANALYSIS
The eyes including the conjunctivas were harvested
and fixed in 10% buffered formalin. Vertical 2 μm-
thick sections were cut and stained with Giemsa. In-
filtrating eosinophils in the lamina propria mucosae of
the tarsal and bulbar conjunctivas throughout each
section were counted by two masked observers. The
sections counted were those of the central portion of
the eye, which included the pupil and optic nerve
head. The data are presented as averages +− SEM
per slide of all the mice examined.
FLOW CYTOMETRIC ANALYSIS
Splenocytes were prepared as described above. To
examine Foxp3 expression in these splenocytes, a
mouse regulatory T cell staining kit (eBioscience,
San Diego, CA, USA) was used according to the
manufacturer’s instructions. The cells were then ana-
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Fig. 3 Suppressive efect of α-GalCer on EC was abrogated by depletion 
of CD4＋CD25＋Foxp3＋T cels. Thymectomized and unthymectomized im-
munocompetent BALB/c mice without treatment of any Abs and α-GalCer 
or vehicle were immunized with RW in alum and 10 days later, they were 
chalenged with RW in eye drops (n＝17 per group). In another set of ex-
periments, thymectomized BALB/c mice were injected intraperitonealy 3 
times with PC61 or nrIgG. Six weeks after birth, the mice were immunized 
with RW in alum and 10 days later, they were chalenged with RW in eye 
drops. Two hours prior to RW chalenge, α-GalCer (Tx＋ PC61＋ α-Gal-
Cer, n＝8 mice) or vehicle (Tx＋PC61＋vehicle, n＝9 mice) was injected 
intraperitonealy. Twenty-four hours after RW chalenge, the conjunctivas 
were harvested and the conjunctival eosinophils were counted. The data 
are presented as means＋/－SEM in each group. ＊＊P＜0.01.
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Table 1 Percentage of Foxp3 expressing in CD4＋CD25＋splenic T cels
% of Foxp3＋in CD4＋CD25＋T cels
16.36＋/－0.23Tx/nrIgG/Vehicle
 23.41＋/－0.10 Tx/nrIgG/α-GalCer
 2.23＋/－0.02Tx/PC61/Vehicle
 1.90＋/－0.09Tx/PC61/α-GalCer
Thymectomized (Tx) mice were intraperitonealy injected with PC61 or nrIgG. These mice were immunized with RW and 
10days later, the mice were chalenged with RW in eye drops. Two hours before RW chalenge, the mice were injected intrape-
ritonealy with either α-GalCer or vehicle. Twenty-four hours after RW chalenge, spleens were harvested for flow cytometric 
analysis to determine the levels of Foxp3 expression.
Data are presented as % of CD4＋CD25＋ splenic T cels that are Foxp3＋. n＝8―10 mice per group.
＊P＜0.001, NS: not significantly diferent.
＊
NS
＊
＊
lyzed on a FACScan (Becton Dickinson, Mountain
View, CA, USA) and the data were acquired and ana-
lyzed by using CellQuest software.
STATISTICAL ANALYSIS OF DATA
Differences between the α-GalCer- and vehicle-
treated mice in terms of flow cytometric data and in-
filtrating eosinophil numbers were tested for signifi-
cance by Student’s t-test. P values less than 0.05 were
considered to indicate significant differences.
RESULTS AND DISCUSSION
To confirm the suppressive effects of α-GalCer on
EC, RW-immunized mice were injected intraperito-
neally with α-GalCer or vehicle 2 hours prior to RW
challenge. Conjunctivas harvested 24 hours after RW
challenge were subjected to histological analysis to
determine the numbers of conjunctival eosinophils.
Identical to our previous report,15 treatment with α-
GalCer significantly suppressed conjunctival eosino-
phil numbers (Fig. 1). In addition, α-GalCer treat-
α-GalCer-Induced CD4+CD25+ T Cells in AC
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ment did not affect conjunctival eosinophil numbers
in naïve mice (Fig. 1), which suggests that the activa-
tion of NKT cells by α-GalCer treatment specifically
affected RW-sensitized immunocompetent cells.
To determine whether CD4+CD25+Foxp3+ T cells
mediate the suppressive effect of α-GalCer treatment
on EC, we depleted CD4+CD25+Foxp3+ T cells from
murine neonates by thymectomy plus PC61 treat-
ment, as previously described.13 At the age of 6
weeks, these mice were then immunized with RW,
treated with α-GalCer or vehicle, and challenged with
RW to induce EC. Twenty-four hours after RW chal-
lenge, the conjunctivas and spleens were harvested
for histological and flow cytometric analyses, respec-
tively. Flow cytometric analysis demonstrated that
thymectomy plus PC61 treatment significantly de-
pleted Foxp3-expressing CD4+CD25+ cells relative to
the numbers observed in thymectomized animals
treated with nrIgG (TxnrIgGvehicle vs TxPC61
vehicle and TxnrIgGα-GalCer vs TxPC61α-
GalCer, Fig. 2, Table 1). Similar to our previous re-
port,15 α-GalCer treatment significantly increased the
numbers of Foxp3-expressing CD4+CD25+ cells in the
nrIgG-treated group (Fig. 2, Table 1). However, α-
GalCer treatment did not affect the Foxp3-expressing
CD4+CD25+ cell numbers in the PC61-treated group
(Fig. 2, Table 1). These data show that α-GalCer
treatment cannot increase CD4+CD25+Foxp3+ T-cell
numbers in the absence of thymus-derived CD4+
CD25+ T cells.
Finally, we investigated whether EC induced in
thymectomized and PC61-treated mice can be sup-
pressed by treatment with α-GalCer. To investigate
whether thymectomy alone affects the severity of EC,
we compared the conjunctival eosinophil numbers
between EC-developing thymectomized and un-
thymectomized immunocompetent mice without
treatment of any Abs and α-GalCer or vehicle. Signifi-
cantly less eosinophils were detected in thymec-
tomized mice (Fig. 3). In accord with conjunctival
eosinophil numbers, the percentage of T cells in
splenocytes was significantly lower in thymectomized
mice (10.9 +− 2.1) than in unthymectomized im-
munocompetent mice (39.0 +− 0.5). Thus, thymec-
tomy alone effectively decreased T cell compartment
and the reduction of T cell population, especially RW-
specific effector T cells, may have attenuated EC de-
velopment in thymectomized mice. On the contrary,
significantly more conjunctival eosinophils were
counted in thymectomized mice treated with PC61
than in thymectomized mice without any treatment
(Fig. 3), similar to our previous report.13 Strikingly,
conjunctival eosinophil numbers were almost the
same between the vehicle-treated and α-GalCer-
treated groups (Fig. 3). These data clearly demon-
strate that thymectomy together with PC61 treatment
abrogate the suppressive effects of α-GalCer on EC.
We previously reported that transfer of CD4+CD25+
Foxp3+ T cells suppressed EC.13 Together with the
findings summarized in Table 1, it appears that the
suppressive effects of α-GalCer on EC are, at least in
part, mediated by CD4+CD25+Foxp3+ T cells.
It has been reported that administration of α-
GalCer expands CD4+CD25+ T cells, which in turn
suppresses the development of experimental autoim-
mune myasthenia gravis (EAMG).16 In that report,
administration of α-GalCer in thymectomized mice in-
creased CD4+CD25+ T-cell numbers. This is in accor-
dance with our observation that α-GalCer treatment
increased CD4+CD25+ T-cell numbers in nrIgG-
treated thymectomized mice (Fig. 2, Table 1). In the
EAMG report, to deplete CD4+CD25+ T cells, anti-
CD25 Ab was injected 15 times starting from when
EAMG was induced. It is certainly conceivable that
this experimental procedure affects not only CD25+
Treg but also CD25+ effector T cells, although the
authors stated that this protocol did not affect EAMG
when α-GalCer was not administered. Furthermore,
data confirming the depletion of CD4+CD25+ T cells
were not shown in the EAMG report. Thus, how anti-
CD25 Ab treatment affects the effects of α-GalCer
was unclear in the EAMG report. Here, in contrast,
we showed the suppressive effects of α-GalCer treat-
ment on EC are abrogated by depletion of CD4+
CD25+ T cells.
Basically, α-GalCer exerts its effects by its nature
as a NKT cell ligand. In a previous report of experi-
mental asthma, it has been pointed out that α-GalCer
inhibits asthma through both NKT cell- and IFN-γ-
dependent pathway.17 It was also reported that pro-
duction of IFN-γ by NKT cells in response to α-
GalCer requires IL-12 produced by dendritic cells
(DCs).18 Thus, it is possible that these mechanisms
other than increase in CD4+CD25+ T cells play a role
in the regulation of EC by treatment with α-GalCer.
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